Kg Of Body Weight Research Articles

On the issue of the effectiveness and bioequivalence of isotretinoin Lidose

BACKGROUND: Acne is one of the most common dermatoses. The most effective drug for the treatment of severe forms of acne is systemic isotretinoin, which affects all links in the pathogenesis of acne. The article presents scientific data on the innovative drug Aknecutan, which uses the patented Lidose technology in its production. The use of isotretinoin in the composition of innovative product with Lidose technology makes it possible to reduce the amount of isotretinoin taken by the patient by 20% without compromising the therapeutic effectiveness of the drug. AIM: to analyze comparative studies of bioavailability and relevant pharmacokinetic parameters, which made it possible to prove that the initial dosages of 8 and 16 mg with Lidose technology are bioequivalent to dosages of 10 and 20 mg of the usual form of isotretinoin. MATERIALS AND METHODS: Over the past 7 years, 1044 patients have received acne treatment for moderate to severe acne (651; 62.4% women and 393; 37.6% men) in a daily dose of 0.4–0.8 mg per 1 kg of body weight with a total dose of the drug ― 100–120 mg/kg per course of therapy. RESULTS: After therapy, clinical remission was achieved in all patients, which required from 7 to 12 months of treatment, depending on the daily dose of the drug. Among the side effects in all patients, cheilitis and retinoic dermatitis of the face were noted, which were completely resolved when using moisturizers and sticks. An increase in liver enzymes, triglycerides and lipoproteins was noted in 5–10% and did not exceed 20–30% of the norm and did not require discontinuation of therapy. At the end of treatment, these indicators returned to normal. Other side effects were extremely rare. Relapses of the disease are most often caused by a low total dose of the drug or the presence of endocrinological and gynecological diseases. CONCLUSION: Thus, innovative product with Lidose technology is one of the most highly effective and safe systemic retinoids for the treatment of moderate to severe acne. Comparative studies of bioavailability and corresponding pharmacokinetic parameters have demonstrated the bioequivalence of isotretinoin in the composition of innovative product with Lidose technology, which fully corresponds to that in the original preparation.

Effects of garlic-derived fructan and oligofructose mixtures on intestinal health and constipation relief in mice.

Garlic polysaccharides (GPs) constitute over 75% of the dry weight of garlic. They are characterized by fructan with a 2,1-β-d-Fruf backbone and 2,6-β-d-Fruf branches. Studies have suggested a role for GPs in regulating gut microbiota but whether they possess a comprehensive function in maintaining intestinal well-being and can serve as effective prebiotics remains unknown. To explore this, varied doses of GPs (1.25-5.0 g kg-1 body weight) and inulin (as a positive control) were administered to Kunming mice via gavage, and their effects on the intestinal epithelial, chemical, and biological barriers were assessed. A constipation model was also established using loperamide to investigate the potential effects of GPs on the relief of constipation. Administration of GPs significantly upregulated expression of tight-junction proteins and mucins in Kunming mouse small-intestine tissue. Garlic polysaccharides elevated cecal butyric acid content, reduced the abundance of Desulfobacterota, and decreased the ratio of Firmicutes to Bacteroidetes (the F/B ratio). Garlic polysaccharides also promoted the growth of Bacteroides acidifaciens and Clostridium saccharogumia. Tax4Fun functional predictions suggested the potential of GPs to prevent human diseases, reducing the risk of insulin resistance, infectious diseases, and drug resistance. Garlic polysaccharides also exhibited a beneficial effect in alleviating loperamide-induced constipation symptoms by enhancing small intestinal transit, softening stool consistency, accelerating bowel movements, and promoting the release of excitatory neurotransmitters. These findings highlight the important role of GPs in maintaining gut fitness by enhancing intestinal barrier function and peristalsis. Garlic polysaccharides are promising prebiotics, potentially contributing to overall intestinal well-being and health. © 2024 Society of Chemical Industry.

PSII-7 Effect of endophyte-infected tall fescue on body weight, vital signs, and liver function of beef heifers

Abstract Tall fescue was first introduced to the United States over 70 years ago. Since then, it has become the most common forage source for beef cattle in the Southeastern region of the US. Most tall fescue establishes a symbiotic relationship with a toxic fungal endophyte (Epichloë coenophiala), which contributes to the improved vigor of the plant due to acquired resistance to grazing, insects, heat, and drought. However, when consumed by cattle, it may cause fescue toxicosis, a condition characterized by reduced feed intake, body weight (BW) loss, vasoconstriction, and impaired reproductive performance in livestock species. Therefore, the aim of this study was to investigate the effect of endophyte-infected tall fescue consumption on growth performance and health-related traits in beef cattle. For this purpose, 24 Simmental x Angus heifers were divided into two dietary treatments, in which 12 heifers received endophyte-free tall fescue seeds (E-) and 12 heifers were fed with endophyte-infected tall fescue seeds (E+, 6,764 ppb of ergovaline) mixed with the diet for 45 d. The E+ heifers received a daily dose of 20 μg of ergovaline per kg of BW. The E- heifers received the same quantity of seeds as the E+ heifers. For each heifer, phenotypes related to growth (BW), vital signs (respiration rate [RR], and body temperature [TEMP]), and liver functions (serum albumin [ALB], alkaline phosphatase [ALP], aspartate aminotransferase [AST], gamma-glutamyltransferase [GGT], cholesterol [COL], bilirubin [BIL], and triglycerides [TRI]) were analyzed at the end of the experiment. Phenotypes were analyzed using a linear model in R with diet included as a fixed effect. For analysis of BW, the BW at the beginning of the trial was included in the model as a covariate. Results showed that COL and ALP were significantly less (P < 0.05) in the E+ heifers compared with the E- (-32.92 ± 11.16 mg/dL and -32.33 ± 13.95 U/L, respectively). Conversely, E+ heifers had greater (P < 0.05) BW, RR, TEMP, and AST when compared with E- heifers (-17.82 ± 5.12 kg, 25.83 ± 5.52 breaths/min, 0.56 ± 0.12 oC, and 5.83 ± 2.18 U/L, respectively). Measurements of ALB, BIL, GGT, and TRI were not different between E+ and E- heifers. Our results suggest that heifers consuming endophyte-infected tall fescue have compromised vital signs and metabolically altered liver, which may impair growth performance. This study increases our understanding of the biological mechanisms affected by the fescue toxin in beef cattle.

232 Evaluation of a phytogenic feed additive with essential oils and plant extracts on growth performance in single sourced steer calves fed a forage-based diet during the initial 53 d receiving period

Abstract The receiving period of a feedlot calf is one of the most stressful stages in the life of that animal and can result in respiratory disease caused, in part, by reduced feed intake and transit stress. Feeding a phytomolecule compound in combination with current therapeutic strategies may aid in controlling systemic inflammation and improve the performance of newly received calves. This study determined whether a phytogenic feed additive with essential oils and plant extracts (PFA) influences measures of growth and growth efficiency during the feedlot receiving phase. The two treatments were a control group fed no additive (CON) and a treatment group fed PFA additive at a rate of 0.25 g/45.4 kg of body weight (BW; PFA). Steers were transported 285 km from an auction facility to the Ruminant Nutrition Center in Brookings, SD where they were vaccinated against viral respiratory diseases and clostridial species, and administered pour-on anthelmintic. Steers were divided into 10 replicate pens of 8 steers (305 ± 30 kg) per treatment (n = 160 steers) in a randomized complete block design. The steers were fed a basal diet [dry matter (DM) basis] containing corn silage (74%), DDGS (21%), a liquid supplement (5%), and monensin sodium (Rumensin-90, Elanco Animal Health) at 25 g/907 kg (DM basis) for 53 d. Steers were fed 2X daily with intakes closely managed for the first 14 d during adaptation to the receiving diet then a slick bunk management strategy was applied for the remainder of the study. No mortality was observed in this study, and one steer was treated for respiratory disease from the CON group. There were no significant differences observed in BW, average daily gain (ADG), variation in ADG, dry matter intake, or feed conversion efficiency from d 1 to 29, 29 to 53, or during the cumulative receiving period (P ≥ 0.11) between the CON and PFA groups. NEm and NEg did not differ between the treatments (P ≥ 0.79). The ratio of observed-to-expected dietary net energy was also not affected by dietary treatment (P ≥ 0.71). The steers used in this study were in good health and had minimal morbidity (0.63%) with no mortality during the 53-d receiving study which contributed to the feed additive having no appreciable influence on the growth and health outcomes in this study.

193 The effects of mannan oligosaccharides on mortality and full value nursery swine

Abstract Mannan oligosaccharides [Actigen; ACT (Alltech, Inc., Nicholasville, KY)] are refined low molecular weight carbohydrates obtained from the cell wall of a specific strain of Saccharomyces cerevisiae. Peer-reviewed studies with nursery swine has suggested that ACT can positively impact intestinal morphology and permeability, inhibit gut colonization of enteric pathogens, and improve the pattern of immune responses with and without viral challenges. To validate these findings, three commercial scale experiments involving a total of 10,634 nursery pigs [PIC 337 × 1050, initially 6.4 kg of body weight (BW)] were conducted. Pens of 36 to 50 mixed sex pigs were randomly assigned to 1 of 2 dietary treatments supplemented with 0 or 800 ppm of ACT, with a total of 112 replications per treatment. In all trials, pigs were fed a nursery program comprised of two phases. Phase 1 from d 0 to 21 (experimental diets) and Phase 2 from d 22-37, 22-43, and 22-44, in Exp. 1, 2, and 3, respectively (common diets). Phase 1 diets were corn-soybean meal based and contained 9% whey permeate, 5% rolled oats, and were formulated to contain 1.38% SID Lysine. Phase 2 diets were corn-soybean meal based and formulated to contain 1.30% SID Lysine. In all experiments, data were analyzed using the GLIMMIX procedure of SAS (Cary, NC) in a randomized complete block design with pen serving as the experimental unit and initial BW serving as blocking factor. Percentage mortality and full value pig were analyzed using a binomial distribution. No significant ACT × experiment interactions (P > 0.10) were observed in mortality or full value pig (Table 1). From d 0 to 21, there was no evidence for differences in average daily gain (ADG), average daily feed intake (ADFI), or gain to feed ratio (G:F; P > 0.10) between dietary treatments (data not showed). From d 0 to 44, mortality was reduced (P < 0.0002), and full value pigs increased (P < 0.0004) in pigs fed diets with 800 ppm compared with pigs fed diets without ACT supplementation. In conclusion, whereas pigs fed diets supplemented with 800 ppm ACT did not show growth performance advantages, these experiments suggest livability and full value pig improvements.

251 Effects of feeding increasing levels of dimethylglycine (DMG) on growth performance, livability, and carcass characteristics of commercial finishing pigs

Abstract This study aimed to evaluate the impact of increasing dietary levels of 78% sodium dimethylglycine (DMG) on growth performance, livability, and carcass characteristics of commercial finishing pigs. A total of 1,115 mixed-sex finishing pigs [initial body weight (BW) = 70.1 ± 1.8 kg] were housed in pens with 25 to 27 pigs per pen. Pens within block were assigned randomly to one of four dietary treatments containing 0 (Control), 0.25 (DMG_0.25), 0.5 (DMG_0.5) or 1.0 (DMG_1.0) g DMG/kg of feed with 11 replicates per treatment. This experiment extended over an 8-wk period until pigs were harvested at 125.4 ± 0.8 kg of BW. Data were analyzed using the MIXED procedure of SAS, and preplanned orthogonal contrasts were conducted to evaluate pairwise comparisons as well as linear and quadratic effects related to the increased levels of DMG. While no linear effect was observed, there was a tendency for a quadratic response in closeout feed efficiency (G/F; P = 0.08) and the percentage of pigs with morbidity (P = 0.06), with the most favorable responses found in pigs fed DMG_0.25 (Table 1). Pairwise comparisons between Control and DMG_0.25 treatments suggest that pigs receiving DMG_0.25 showed a 6% increase in closeout average daily gain (ADG; 1.01 vs. 0.95 kg/d; P = 0.02) and a 4% increase in closeout G/F (0.337 vs. 0.324; P = 0.05) compared with those fed Control diet. Furthermore, DMG supplemented at 0.25 g/kg tended to be associated with decreased mortality (P = 0.08), reduced morbidity (P = 0.09) and more pigs sold to the primary market (P = 0.10) compared with Control. In contrast, dietary supplementation of greater concentrations of DMG at 0.5 and 1.0 g/kg were not different compared with Control (P > 0.10). Carcass characteristics, including hot carcass weight, carcass yield, fat depth, loin depth, and fat-free carcass lean, were not different among treatments. The findings of this study suggest dietary supplementation of DMG at 0.25 g/kg of feed enhanced growth performance and livability in finishing pigs. However, feeding greater concentrations of DMG, up to 1.0 g/kg of feed, did not produce different outcomes compared with Control. These results indicate the potential benefits of DMG at specific inclusion rate in optimizing the production and health of finishing pigs.

Abstract PO3-28-05: Therapeutic Plasmapheresis as a Symptomatic Treatment for Paclitaxel-Associated Peripheral Polyneuropathy

Abstract Relevance: Paclitaxel-associated peripheral polyneuropathy (PIPN) is one of the most common side effects that develop during treatment with drugs of the taxane group. In the treatment of early breast cancer with paclitaxel 80 mg/m2 weekly, 12 injections, PINP develops in 90% of patients of varying severity. The main symptoms are pain and numbness in the arms and legs, which is associated with the accumulation of paclitaxel in the ganglia of the spinal cord, as well as increased expression in the ganglia of the spinal cord of chemokines and cytokines, such as IL-1β, IL-8 and TNF-α, as well as CXCR4, RAGE, CXCL1, CXCL12, CX3CL1 and C3. We hypothesized that the severity of PIPN symptoms can be reduced by lowering the concentration of chemokines and cytokines in the blood by performing plasmapheresis sessions. Research methods: An open prospective study was carried out, the protocol of which was approved by the ethical committee. The study included 30 patients (100% women) aged 30 to 60 years (mean age 45 years) who developed PIPN during paclitaxel therapy 80 mg/m2, weekly, 12 injections. The severity of PIPN symptoms was assessed using a “visual analogue scale” (VAS). The results of the VAS evaluation varied from 6 to 8 points. Patients underwent 5 courses of membrane plasmapheresis with exfusion of 400-500 ml of plasma per session (20 ml per 1 kg of body weight), plasma loss was compensated with saline. Repeated procedures were performed once every two months for 6 months. Results: 30 patients underwent 15 procedures of therapeutic plasmapheresis within 6 months. In 21 patients (70%) there was a pronounced decrease in PIPN symptoms (VAS - 2-3 points), in 3 patients (10%) a moderate decrease in symptoms (VAS -5-6 points), in 6 (20%) no effect of plasmapheresis (VAS - 7-8 points). Approximately 15% of procedures were associated with adverse events, the most common of which were vasovagal reactions; 20% of patients had at least one adverse event. Conclusions: Given the subjective reduction in the severity of PIPN symptoms during courses of therapeutic plasmapheresis in more than 70% of cases, therapeutic plasmapheresis can be used as a symptomatic therapy for PIPN, however, taking into account the subjective assessment of the results by patients, there may be a risk of developing cognitive errors. Therefore, this method of therapy requires more thorough study. Citation Format: Sardor Abdugafforov, Vladimir Vorotnikov, Alexander Soynov, Tornike Mchedlidze, Igor Kopytich, Sofia Kim. Therapeutic Plasmapheresis as a Symptomatic Treatment for Paclitaxel-Associated Peripheral Polyneuropathy [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO3-28-05.

Therapeutic effects of lincomycin and level of drug degradation in broiler tissues after treatment

Background and Aim: Lincomycin is an antibiotic used in broiler farming and is commonly combined with other substances to achieve synergistic and complementary effects on the antibacterial spectrum and mechanism. We developed a specific high-performance liquid chromatography (HPLC) method to measure lincomycin levels in broiler tissues. This study aimed to determine the lincomycin level in tissues and compare it with the minimum inhibitory concentration (MIC) and maximum residue limit (MRL) of certain pathogenic bacteria. Materials and Methods: Three groups of broiler chickens were involved in the study (n = 20 in each group): A control group without lincomycin treatment and two groups (each further divided into two sub-groups) that received oral lincomycin at a dose of 1 g/10 kg of body weight daily for 7 and 14 consecutive days. Tissue samples were collected from each group 1 day and 1 week after lincomycin administration (ALA). This study validated the development of a technique for analyzing drug level degradation in tissues using HPLC. Descriptive and statistical analyses were performed for drug levels to assess their therapeutic value and safety based on lincomycin MIC of certain pathogenic bacteria and MRL. Results: The method validation resulted in linear regression and coefficient of determination for tissues with r2 > 0.99, with a recovery rate of 90%–110%, precision as the coefficient of variation 15%, and specificity with no peak overlap for lincomycin. The limits of detection for the liver and kidney were 0.01 μg/g, 0.05 μg/g, and 0.1 μg/g for the breast muscle and all tissues. Administration of lincomycin for 7 and 14 days resulted in therapeutic value concentrations. Lincomycin levels in the liver and kidney of ALA exceeded the MRL, whereas breast muscles were below the MRL for a week of ALA treatment. Conclusion: Administration of lincomycin for 7 and 14 consecutive days resulted in therapeutic value; however, after a week, most tissues showed high drug concentrations that exceeded the MRL. It is necessary to carefully consider the prolonged therapeutic dose of lincomycin in broilers. Antibiotic therapy must be guided in such a way as to protect the product from harmful residues. Keywords: : broiler tissues, lincomycin level, maximum residue limit, minimum inhibitory concentration.

Acute effects of a ketone monoester, whey protein, or their co-ingestion on mTOR trafficking and protein-protein co-localization in human skeletal muscle.

We recently demonstrated that acute oral ketone monoester intake induces a stimulation of postprandial myofibrillar protein synthesis rates comparable to that elicited following the ingestion of 10 g whey protein or their co-ingestion. The present investigation aimed to determine the acute effects of ingesting a ketone monoester, whey protein, or their co-ingestion on mTOR-related protein-protein co-localization and intracellular trafficking in human skeletal muscle. In a randomized, double-blind, parallel group design, 36 healthy recreationally active young males (age: 24.2±4.1 y) ingested either: 1) 0.36 g ∙ kg-1 bodyweight of the ketone monoester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (KET), 2) 10 g whey protein (PRO), or 3) the combination of both (KET+PRO). Muscle biopsies were obtained in the overnight postabsorptive state (basal conditions), and at 120- and 300-minutes in the postprandial period for immunofluorescence assessment of protein translocation and co-localization of mTOR-related signaling molecules. All treatments resulted in a significant (Interaction: P<0.0001) decrease in tuberous sclerosis complex 2 (TSC2)-Ras homolog enriched in brain (Rheb) co-localization at 120-minutes vs. basal; however, the decrease was sustained at 300-minutes vs. basal (P<0.0001) only in KET+PRO. PRO and KET+PRO increased (Interaction: P<0.0001) mTOR-Rheb co-localization at 120-minutes vs. basal; however, KET+PRO resulted in a sustained increase in mTOR-Rheb co-localization at 300-minutes that was greater than KET and PRO. Treatment intake increased mTOR-wheat germ agglutinin (WGA) co-localization at 120- and 300-minutes (Time: P=0.0031), suggesting translocation toward the fiber periphery. These findings demonstrate that ketone monoester intake can influence the spatial mechanisms involved in the regulation of mTORC1 in human skeletal muscle.

SAFETY ASSESSMENT OF AYURVEDIC GOLD MEDICATION SUVARNA BHASMA, IN WISTAR RATS

Suvarna bhasma (SB) contains gold and lead, which are highly potent metals and are toxic in their crude form. This study evaluated the safety profile of the medication. Suvarna bhasma was administered for 90 consecutive days orally at three doses (10.23 mg kg-1, 40.92 mg kg-1 and 102.3 mg kg-1 body weight) to wistar rats. Clinical observations, feed and water consumption, and body weight changes were noted during the study period. On the 91st day, hematological, biochemical and histopathological changes were studied. There was a significant decrease in body weight of rats at a low dose (10.23 mg kg-1) at fourth week, which could not be correlated with feed and water consumption findings. Thus, change was not considered as a treatment-related effect. Suvarna bhasma showed no evident untoward effect in haematological, biochemical and histopathological parameters in the 90 day-subchronic toxicity study (OECD 408 guidelines) and was safe in Wistar rats.

Adaptive thermogenesis, at the level of resting energy expenditure, after diet alone or diet plus bariatric surgery.

The objective of this study was to compare the magnitude of adaptive thermogenesis (AT), at the level of resting energy expenditure (REE), after a very low-energy diet alone or combined with Roux-en-Y gastric bypass or sleeve gastrectomy, as well as to investigate the association between AT and changes in appetite. A total of 44 participants with severe obesity underwent 10 weeks of a very low-energy diet alone or combined with Roux-en-Y gastric bypass or sleeve gastrectomy. Body weight and composition, REE, subjective appetite feelings, and plasma concentrations of gastrointestinal hormones were measured at baseline and week 11. AT, at the level of REE, was defined as a significantly lower measured versus predicted (using a regression model with baseline data) REE. Participants lost 18.4 ± 3.9 kg of body weight and experienced AT, at the level of REE (-121 ± 188 kcal/day; p < 0.001), with no differences among groups. The larger the AT, at the level of REE, the greater the reduction in fasting ghrelin concentrations and the smaller the reduction in feelings of hunger and desire to eat in the postprandial state. Weight-loss modality does not seem to modulate the magnitude of AT, at the level of REE. The greater the AT, at the level of REE, the greater the drive to eat following weight loss.

Pharmacokinetics of tilmicosin in plasma, urine and feces after a single intragastric administration in donkey (Equus asinus).

Tilmicosin, a macrolide antibiotic, has the potential to treat bacterial infections in donkeys. However, the pharmacokinetics of tilmicosin in donkeys have not been reported. The aim of this study was to investigate the pharmacokinetics of tilmicosin in donkey plasma, urine, and feces after a single intragastric administration to determine the suitability of tilmicosin for donkeys. A total of 5 healthy male donkeys with similar body weights were selected. The donkeys were administered a single dose of 10 mg · kg-1 body weight (BW) tilmicosin by gavage. The concentrations of tilmicosin in plasma, urine, and feces were determined. The results showed that after a single intragastric administration of 10 mg · kg-1 body weight, tilmicosin in donkey plasma reached a maximum concentration of 11.23 ± 5.37 mg · L-1 at 0.80 ± 0.10 h, with a half-life of 14.49 ± 7.13 h, a mean residence time of 28.05 ± 3.05 h, a Cl/F of 0.48 ± 0.18 L · kg-1 · h-1, and a Vd/F of 9.28 ± 2.63 Lkg-1. The percentage of tilmicosin excreted through the urine of donkeys is 2.47%, and the percentage excreted through the feces is 66.43%. Our study provides data to inform the use of tilmicosin in donkeys.

Pharmacological validation of an attention bias test for conventional broiler chickens.

Fear and anxiety are considered concerns for animal welfare as they are associated with negative affective states. This study aimed to pharmacologically validate an attention bias test (ABT) for broiler chickens (Gallus gallus domesticus) as a cognitive bias test to determine anxiety. Two-hundred-and-four male Ross 708 broiler chickens were arbitrarily allocated to either the anxiogenic or control treatment at 25 days of age (n = 102/treatment). Birds from the anxiogenic group were administered with 2.5 mg of β-CCM (β-carboline-3-carboxylic acid-N-methylamide [FG 7142]) per kg of body weight through an intraperitoneal injection (0.1 ml/100 g of body weight). Birds from the control group were administered with 9 mg of a saline solution per kg of body weight. During ABT, birds were tested in groups of three (n = 34 groups of three birds/treatment) with commercial feed and mealworms as positive stimuli and a conspecific alarm call as a negative stimulus. Control birds were 45 s faster to begin feeding than anxiogenic birds. Birds from the control group vocalized 40 s later and stepped 57 s later than birds from the anxiogenic group. The occurrence of vigilance behaviors did not differ between treatments. This study was successful in pharmacologically validating an attention bias test for fast-growing broiler chickens, testing three birds simultaneously. Our findings showed that latencies to begin feeding, first vocalization, and first step were valid measures to quantify anxiety.

Impact of postpartum weight change on metabolic syndrome and its components among women with recent gestational diabetes mellitus

BackgroundWhile postpartum weight changes may affect the levels of metabolic parameters, the direct effects of weight changes in the postpartum period on changes in the prevalence rates of metabolic syndrome and its components remain unstudied. This study aimed to investigate the effects of postpartum weight changes between 6 weeks and 6 months on changes in the prevalence rates of metabolic syndrome and its components in women who have recently experienced gestational diabetes mellitus.MethodsThis prospective cohort study included 171 postpartum women with recent gestational diabetes mellitus, who underwent serial weight and metabolic risk factor assessments at 6 weeks and 6 months postpartum. Weight changes between these time points were classified as weight loss (> 2 kg), weight stability (± 2 kg), or weight gain (> 2 kg). Metabolic syndrome comprised the following metabolic risk factors: large waist circumference, elevated blood pressure, elevated fasting plasma glucose levels, high triglyceride levels, and low high-density lipoprotein cholesterol levels.ResultsOf the 171 women in our cohort, 30 women (17.5%) lost > 2 kg of body weight, while 85 (49.7%) maintained a stable weight and 56 (32.8%) gained > 2 kg. The weight loss group experienced significant changes in the prevalence rates of the following metabolic risk factors compared to the weight stability and weight gain groups: large waist circumference (% change: − 26.7 vs − 5.9 vs 5.4, respectively; p = 0.004), elevated fasting plasma glucose levels (% change: − 3.4 vs 18.9 vs 26.8, respectively; p = 0.022), and high triglyceride levels (% change: − 30.0 vs 0 vs − 7.2, respectively; p = 0.024). A significantly greater decrease in the prevalence of metabolic syndrome was also found in the weight loss group than in the other two groups (% change: − 20.0 vs 11.8 vs 14.2, respectively; p = 0.002).ConclusionsWeight changes from 6 weeks to 6 months postpartum significantly altered the prevalence rates of metabolic syndrome and its components in women with recent gestational diabetes mellitus. Early postpartum weight loss can reverse metabolic risk factors and reduce the prevalence of metabolic syndrome.Trial registrationThai Clinical Trials Registry: Registration no. TCTR20200903001. Date of registration: September 3, 2020. Date of initial participant enrolment: September 7, 2020.

Influence of Patient Weight on Prehospital Advanced Airway Procedure Success Rates

ABSTRACT Objective: Previous investigations of the relationship between obesity and difficult airway management have provided mixed results. Almost universally, these studies were conducted in the hospital setting, and the influence of patient body weight on successful prehospital airway management remains unclear. Because patient weight could be one readily identifiable risk factor for problematic airway interventions, we sought to evaluate this relationship. Methods: We conducted a retrospective analysis using the 2020 ESO Data Collaborative dataset. The inclusion criteria consisted of adult patients weighing >30kg with an attempted orotracheal intubation (OTI) and/or blind insertion airway device (BIAD) placement. Separate logistic regression models were developed to determine the influence of weight (dichotomized at 100kg) on cumulative procedure success for OTI and BIAD, and linear regression models were used to identify trends for each across weight strata. Results: A total of 45,344 patients met inclusionary criteria, among which 40,668(89.7%) suffered from a medical emergency, followed by 3,130(6.9%) with traumatic injuries, and 1,546(3.4%) attributable to a combined medical-trauma etiology. Cardiac arrest occurred either prior to EMS arrival or at some point during EMS care in 38,210(84.3%) patients. OTI was attempted in 18,153(40.0%) patients, while 21,597(47.6%) had a BIAD attempt and 5,594(12.3%) had both airway types attempted. The overall cumulative insertion success rates for OTI and BIAD were 79.5% and 92.7%, respectively. Altogether, 2,711(6.0%) had no advanced airway of any type successfully placed, which represents the overall failed advanced airway rate. After controlling for patient age, sex, minority status, and call type (medical vs. trauma), weight >100kg was associated with decreased likelihood of cumulative OTI success (OR = 0.64,p < 0.001), but higher likelihood of cumulative BIAD success (OR = 1.31,p < 0.001). Cumulative OTI success was associated with a negative 0.6% linear trend per 5kg of body weight (p < 0.001) while cumulative BIAD success had a 0.2% positive trend (p < 0.001). Conclusion: This retrospective analysis of a national EMS database revealed that increasing patient weight was negatively associated with intubation success. A positive, but smaller, linear trend was observed for BIAD placement. Patient weight may be an easily identifiable predictor of difficult oral intubation and may be a consideration when selecting an airway management strategy.

Anthelmintic efficacy of an organic fraction from Guazuma ulmifolia leaves and evaluation of reactive oxidative stress on Haemonchus contortus

This study describes the anthelmintic efficacy of an organic fraction (EtOAc- F) from Guazuma ulmifolia leaves and evaluation of its reactive oxidative stress on Haemonchus contortus. The first step was to assess the anthelmintic effect of EtOAc-F at 0.0, 3.5, 7.0 and 14 mg kg of body weight (BW) in gerbil’s (Meriones unguiculatus) artificially infected with H. contortus infective larvae (L3). The second step was to evaluate the preliminary toxicity after oral administration of the EtOAc-F in gerbils. Finally, the third step was to determine the relative expression of biomarkers as glutathione (GPx), catalase (CAT), and superoxide dismutase (SOD) against H. contortus L3 post-exposition to EtOAc-F. Additionally, the less-polar compounds of EtOAc-F were identified by gas mass spectrophotometry (GC-MS). The highest anthelmintic efficacy (97.34%) of the organic fraction was found in the gerbils treated with the 14 mg/ kg of BW. Histopathological analysis did not reveal changes in tissues. The relative expression reflects overexpression of GPx (p˂0.05, fold change: 14.35) and over expression of SOD (p˂0.05, fold change: 0.18) in H. contortus L3 exposed to 97.44 mg/mL of EtOAc-F compared with negative control. The GC-MS analysis revealed the presence of 4-hydroxybenzaldehyde (1), leucoanthocyanidin derivative (2), coniferyl alcohol (3), ferulic acid methyl ester acetate (4), 2,3,4-trimethoxycinnamic acid (5) and epiyangambin (6) as major compounds. According to these results, the EtOAc-F from G. ulmifolia leaves exhibit anthelmintic effect and increased the stress biomarkers on H. contortus.

The Impact of Neocidol on Hematological Parameters in Swiss Albino Mice

Neocidol, containing Diazinon, stands as a prevalent compound in the fields of plant protection and insect control for public health. Despite its historical prominence, Neocidol, classified as a non-systemic organophosphate, exerts its effects by inhibiting cholinesterase, a pivotal enzyme in nerve transmission. In light of the widespread use of Neocidol in Libya and the absence of local studies, this research endeavors to assess its impact on blood parameters and the biochemistry of female white mice. The study involves prolonged tests wherein a sublethal concentration of 15 µl Neocidol per kg of body weight is introduced through the mice's drinking water. Toxicity assessments reveal noteworthy distinctions in various blood parameters between treated and untreated mice. Treated mice exhibit elevated leukocyte and erythrocyte values, coupled with diminished MCHC and MCV values. While blood chemistry results generally align between the control and treatment groups, an exception is observed in the form of heightened Alk-phosphatase values in treated mice. In summary, despite Neocidol's historical favorability in agricultural and public health pest control, this study underscores emerging criticisms concerning its identified health and environmental implications.

Response to Incremental Replacement of Palm Oil with Fish Oil in Starter Diet on Growth Performance, Plasma Metabolites, Ruminal Fermentation, and Behavior of Dairy Calves.

The objective of this study was to evaluate the effects of the incremental levels of n-3 fatty acids (FA) in starter feed (SF) on growth and metabolic performance of milk-fed calves. From day 3 of age, 30 female calves (39.4 ± 3.1 kg of body weight) were randomly assigned to one of three dietary treatments: (1) SF supplemented with 3.3% palm fatty acids (PO), (2) SF supplemented with 1.7% of PO and 1.9% fish oil (PFO), or (3) SF supplemented with 3.9% fish oil (FO). Chopped straw (7.5% of DM) was included in the SF of all treatments as total mixed ration (TMR). Diets had similar energy and protein contents. Total n-3 FA (% of total FA) and n-6/n-3 of PO, PFO, and FO were 1.90, 6.80, and 11.8 and 15.5, 4.50, and 2.70, respectively. The BW was greater for calves receiving FO (60.2 ± 0.3 kg) compared with PFO (58.7 ± 0.3 kg; p = 0.007) and tended to be greater for calves receiving FO vs. PO (59.0 ± 0.3 kg; p = 0.050). Because there was no interaction effect between diet × week of experiment, the greater BW of FO could not be attributed to the dietary treatment. Accordingly, average daily gain, total dry matter intake (DMI), starter DMI, and gain to intake ratio (G:FI) did not differ among dietary treatments during the entire period of the study (p > 0.05). Dietary treatments did not impact body size parameters such as body length, body girth, withers height, heart girth, hip height, and width (p > 0.05). Neither ruminal fermentation parameters nor blood variables were influenced by supplementing the types of oil at different time points. Calves' behavioral parameters, such as standing, lying, eating, and ruminating, were not influenced by different dietary treatments (p > 0.05). The number of days with abnormal fecal score was not different among dietary groups (p > 0.05). Overall, our findings suggest that changing the n-6/n-3 ratio in starter feed by incremental replacement of palm fatty acid with fish oil at a moderate supplemental level of ~3% of DM may not affect the growth and metabolic performance of young calves under non-challenged conditions.

CAPE ameliorates vascular damage caused by sepsis

parameters of vascular and oxidative damage caused by sepsis and to evaluated the effects of caffeic acid phenethyl ester (CAPE) on these damages.&#x0D; Materials and Methods: Wistar-Albino male rats were used for this study. Rats were divided into 4 groups (n = 10). Group 1 animals were intraperitoneally (i.p) injected with sterile saline (Control Group). Group 2 animals were i.p injected with lipopolysaccharide (LPS), 20 mg / kg-weight dose (Sepsis Group). Group 3 animals were i.p injected with lipopolysaccharide, 20 mg / kg-weight dose. Immediately after LPS injection, CAPE was i.p injected at single dose, 10 µmol / kg-body weight (Treatment Group). A single dose of CAPE, 10 µmol / kg-body weight / day, was injected i.p to Group 4 animals for 5 days. After 5th day CAPE injection, a single dose of LPS 20 mg / kg-weight was injected (Protective Group). At the 6th hour after the injections applied to all groups, blood sample were taken intracardiac and their serum were separated for the studies. Homocysteine (Hcy), asymmetric dimethyl arginine (ADMA), endothelin-1 (ET-1) and vascular cellular adhesion molecule-1 (VCAM-1) were measured by enzyme-linked immunosorbent assay (ELISA). In addition, the protective and therapeutic effects of CAPE on these parameters was investigated.&#x0D; Results: Control group Hcy, ADMA, ET-1 and VCAM-1 levels were found to be 4.987 ± 0.096 µmol/l, 0.803 ± 0.020 nmol/ml, 21.123 ± 2.575 ng/l, 3.155 ± 0.078 ng/ml, respectively. Sepsis group Hcy, ADMA, ET-1 and VCAM-1 levels were found to be 8.975 ± 0.160 µmol/l, 3.953 ± 0.678 nmol/ml, 52.446 ± 2.546 ng/l, 10.783 ± 1.068 ng/ml, respectively. Treatment group Hcy, ADMA, ET-1 and VCAM-1 levels were found to be 5.286 ± 0.037 µmol/l, 1.304 ± 0.040 nmol/ml, 27.995 ± 1.299 ng/l, 3.72 ± 0.073 ng/ml, respectively. Protective group Hcy, ADMA, ET-1 and VCAM-1 levels were found to be 5.401 ± 0.042 µmol/l, 1.431 ± 0.056 nmol/ml, 32.708 ± 1.326 ng/l, 4.058 ± 0.069 ng/ml, respectively. It was observed that the Hcy, ADMA, ET-1 and VCAM-1 levels of the sepsis group increased significantly compared to the control group (p0.05). It was observed that CAPE treatment significantly decreased these parameters levels. However, the use of CAPE as a protective was not as effective as its treatment effect.&#x0D; Conclusion: Our results demonstrated that sepsis resulted in increase Hcy, ADMA, ET-1, VCAM-1 levels. All these changes indicate that sepsis-mediated vascular damage is increased. Our results demonstrated that CAPE is more effective in preventing sepsis-mediated damages when given as a treatment.

Effects of Nano Selenium on Some Metabolic and Rumen Parameters in Dorper Sheep

The aim of the study was to investigate the effects of nano selenium (N-Se) supplementation on some metabolik parameters and rumen fermentation in sheep. In the study, twenty female Dorper sheep, average 60.1±0.44 kg of body weight were used and blood samples and rumen fluid were taken at the end of trial. The animals were randomly divided into two trial groups (n=10). The control animals received the basal ration without Se supplementation, containing a native Se content of 0.06 mg/kg DM. The other sheep were fed the same basal ration supplemented with 3 g/head/day N-Se. Trial were 66 days with 10 days of adaptation to feed and 56 days of feeding period. Serum total protein (p=0.514) and albumin (p=0.126) levels did not change by feeding N-Se. Serum T-cholesterol, triglycerides, AST (p=0.001) and ALT (p=0.030) levels were decreased in the N-Se-treated group when compared with the control. Supplementation of N-Se did not effect ruminal pH values (p=0.792), the molar concentration of acetic acid (p=0.133) and butyric acid (p=0.089), but the ammonia concentration (p=0.001) was decreased, and total VFA concentration (p=0.003) was increased. The ratio of acetate to propionate decreased due to the increasing of propionate concentration (p=0.034). The obtained results indicated that N-Se supplementation positively improved ruminal fermentation and metabolic status. It was concluded that N-Se can be used as an alternatively available selenium source in sheep.